Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine add-on to alpha-blocker in men with OAB
NCT00546637Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in overactive bladder syndrome (OAB) comparing Fesoterodine with Placebo (2 arms). Primary endpoint: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at 12 weeks. Started Nov 2007; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00546637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546637.